Physician profile
Tresy Thomas
NPI 1881090744
$5,697.24
in general payments reported to CMS, 2019-2025
30 companies · $852 in 2025
The $852 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $926 · 2022: $1,022 · 2023: $1,347 · 2024: $1,551 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,688 · Education: $62.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,687.64 |
| Education | $62.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $976.61 | 2021-2025 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $675.92 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $659.52 | 2021-2024 | Jardiance |
| Abiomed | $532.67 | 2023-2025 | Impella |
| Janssen Pharmaceuticals, INC | $409.43 | 2022-2024 | Xarelto |
| Amgen INC. | $314.94 | 2022-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $295.50 | 2021-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $257.40 | 2022-2025 | Mitraclip, Cardiomems, I-Stat |
| Chiesi USA, INC. | $246.88 | 2021-2025 | Kengreal |
| Esperion Therapeutics, INC. | $237.41 | 2021-2022 | |
| Pfizer INC. | $206.37 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $202.55 | 2023-2025 | |
| Medtronic, INC. | $151.05 | 2025 | Symplicity G3 |
| Silk Road Medical, INC. | $87.55 | 2022 | |
| Saranas, INC. | $57.52 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $55.26 | 2021-2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $49.08 | 2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $37.35 | 2024-2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $33.71 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $32.29 | 2024 | Optowire, Cardiva Vascade Mvp Vvcs 6-12f |
| Procyrion, INC. | $28.66 | 2025 | Aortix System |
| Angiodynamics, INC. | $21.72 | 2023 | Bioflo |
| Scpharmaceuticals INC. | $21.35 | 2024 | |
| Daxor Corporation | $20.42 | 2023 | Bva-100 |
| Ancora Heart, INC. | $17.42 | 2024 | Accucinch |
| Shockwave Medical, INC | $14.91 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.60 | 2024 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $14.22 | 2024 | |
| Merck Sharp & Dohme LLC | $13.81 | 2021 | |
| Impulse Dynamics (USA) INC. | $11.12 | 2025 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tresy Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.